← ANALYST RATINGS · TIPRANKS
Greenwich LifeSciences (GLSI): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $69.00, the highest $69.00, the lowest $69.00. The average is +374.2% from the last price of $14.55.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $50.00 → $69.00+38.0% | Buy | +374.2% | Reiterated | 21.07.26on TipRanks Jul 27 21:07 | +3.3%next day −9.3% · 5 days −7.2% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $45.00 | Buy | +209.3% | Reiterated | 02.06.26on TipRanks 09:30 | −14.9%next day +0.7% · 5 days −5.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Greenwich LifeSciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $69.00 at a price of $18.05 (+282.3%); now: $69.00 at $14.55 (+374.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 2 | 2 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Greenwich LifeSciences
- CEO: Snehal S. Patel
- Employees: 13
- Building 14, Stafford, TX, 77477, US
- greenwichlifesciences.com
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Data from the stock’s TipRanks forecast page, read 372 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗